Endocrinology & AI

Research and developments at the intersection of artificial intelligence and healthcare.

Why it matters: AI is transforming how we diagnose, treat, and prevent disease. Staying informed helps clinicians and patients make better decisions.

9 research items

Get updates on this topic

Sort by Date Sort by Relevance

Safety Alert

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

From: 2026-06-08

Nature Medicine - AI Section⭐Promising2 min read

Weekly Injection Cuts Liver Fat and Weight in New Trial

Key Takeaway:

A new weekly injection called survodutide significantly reduces both liver fat and body weight in adults with obesity and metabolic liver disease, offering a promising dual-action treatment within the next few years.

Researchers studied a new weekly injection called survodutide for adults struggling with obesity and a common liver condition called MASLD, which causes harmful fat buildup in the liver. In this high-quality study, patients who received the weekly injection lost significant body weight and successfully lowered the amount of fat in their livers compared to those who took a dummy shot, or placebo. This is important because excess liver fat can lead to permanent liver damage. While this treatment is not yet available at local pharmacies, it represents a major step forward in helping people manage both weight and liver health with a single medication.

What this means for you

A weekly injection called survodutide was shown to reduce liver fat and body weight. This promising treatment is still being studied and is not yet available; do not alter your current medical care.

Clinical Trial Endocrinology

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04479-3 Read article →

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

From: 2026-06-08

Nature Medicine - AI Section⭐Promising2 min read

New Weight-Loss Pill Shows Promising Results in Clinical Trial

Key Takeaway:

An oral pill called aleniglipron helped adults with overweight or obesity lose up to 11.3% of their body weight over 36 weeks in a mid-stage clinical trial.

Researchers tested a new weight-loss pill called aleniglipron, which belongs to the same family of highly effective medications as current weekly weight-loss injections. The study looked at 230 adults who were overweight or had obesity. After taking the pill for 36 weeks, participants lost up to 11.3% of their body weight compared to those who took a dummy pill (placebo). This is exciting because a simple daily pill would be much easier for many people to take and store than weekly shots. While these early results are very promising, the drug must still go through larger, final-stage testing before it can be approved for the public.

What this means for you

A new daily weight-loss pill showed promising results in a 36-week study of 230 adults. It is still in testing and not yet available, so do not alter your current treatment plan.

Endocrinology Clinical Trial

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04476-6 Read article →

From: 2026-06-05

Nature Medicine - AI Section⭐Promising2 min read

New Daily Pill Shows Promise for Significant Weight Loss

Key Takeaway:

An oral weight-loss pill called aleniglipron helped adults lose up to 11.3% of their body weight over 36 weeks, offering a potential needle-free alternative to current injections.

Researchers studied a new weight-loss pill called aleniglipron, which belongs to the same family of medications as popular weekly weight-loss injections. In a study of 230 adults who were overweight or obese, those taking the daily pill lost up to 11.3% of their body weight over 36 weeks compared to those taking a dummy pill (placebo). This is exciting because many people prefer taking a simple pill over giving themselves weekly shots. While these early results are very promising, the drug must still undergo larger, longer studies to prove it is completely safe and effective before it can be prescribed by doctors.

What this means for you

A new daily weight-loss pill showed promising results in a 230-person study, but it is still in testing and not yet available. Please consult your doctor before changing any treatments.

Endocrinology Clinical Trial

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04476-6 Read article →

Safety Alert

Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes

From: 2026-02-27

Nature Medicine - AI Section⭐Promising3 min read

Y chromosome genetic variations linked to diabetes risk

Key Takeaway:

Research shows that genetic changes on the Y chromosome may influence type 2 diabetes risk differently in East Asian and European men, highlighting a new area for personalized treatment approaches.

In a massive genetic study of over 300,000 males, researchers investigated how the Y chromosome influences type 2 diabetes risk. They discovered that the loss of the Y chromosome, a change that can occur over time, affects diabetes susceptibility differently in men of East Asian descent compared to those of European descent. This finding reveals a new genetic contributor to metabolic health.

What this means for you

Early research suggests the Y chromosome may affect type 2 diabetes risk. It's not ready for clinical use yet. Keep following your current treatment plan and consult your doctor for personalized advice.

Endocrinology Observational Study Radiology

Citation:

Nature Medicine - AI Section, 2026. Read article →

Safety Alert

From: 2026-02-25

Nature Medicine - AI Section⭐Exploratory3 min read

Y chromosome loss linked to population-specific diabetes risk

Key Takeaway:

Research shows that genetic changes on the Y chromosome affect type 2 diabetes risk differently in East Asian and European men, highlighting the need for population-specific approaches in diabetes care.

A large-scale genetic study of over 300,000 male participants has revealed that genetic changes and the loss of the Y chromosome affect type 2 diabetes risk differently in East Asian and European men. By analyzing genetic, protein, and metabolic data, researchers found that the biological consequences of losing the Y chromosome are population-specific. This discovery highlights the limitations of one-size-fits-all medicine and underscores the urgent need to include diverse genetic backgrounds when designing diabetes treatments and risk assessments.

What this means for you

This early research suggests genetic factors on the Y chromosome may affect type 2 diabetes risk. It's not ready for clinical use yet. Continue following your doctor's advice and current care plan.

Endocrinology Observational Study Radiology

Citation:

Nature Medicine - AI Section, 2026. Read article →

Safety Alert

From: 2026-02-23

Nature Medicine - AI Section⭐Promising3 min read

Y chromosome loss linked to type 2 diabetes risk

Key Takeaway:

Loss of the Y chromosome may increase type 2 diabetes risk differently in East Asian and European men, highlighting the need for population-specific genetic research.

To understand the genetic roots of metabolic disorders, researchers conducted a massive genetic study involving over 300,000 male participants. They focused on how the loss of the Y chromosome affects the risk of developing type 2 diabetes. By examining pancreatic cells, the team discovered that losing this chromosome alters glucose metabolism. Crucially, the study revealed that this genetic effect varies significantly between East Asian and European men. These findings emphasize that genetic risk factors are not universal, highlighting the urgent need for population-specific research to design effective, personalized prevention and treatment strategies.

What this means for you

This early research on the Y chromosome's role in type 2 diabetes is promising but not yet ready for clinical use. Continue following your doctor's advice and don't change your care based on this study.

Endocrinology Observational Study Radiology

Citation:

Nature Medicine - AI Section, 2026. Read article →

From: 2026-02-18

Nature Medicine - AI Section⭐Exploratory3 min read

Diabetes patients demand personal outcomes in stem cell therapy

Key Takeaway:

Patients with type 1 diabetes stress that stem-cell-derived islet cell therapy should focus on outcomes that matter most to them, guiding future treatment evaluations.

A qualitative study gathered insights from adults living with type 1 diabetes regarding stem-cell-derived islet cell therapy. Through structured interviews and focus groups, participants shared their specific expectations and concerns about this emerging treatment. The study highlights that clinical trials must focus on patient-defined outcomes rather than just laboratory metrics to ensure new therapies truly improve the daily lives and acceptance of those living with the condition.

What this means for you

This research emphasizes patient priorities in diabetes treatment. It's early-stage, so years away from availability. Continue with your current care plan and discuss any questions with your doctor.

Clinical Trial Endocrinology

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04201-3 Read article →

From: 2026-01-05

ArXiv - Quantitative BiologyExploratory3 min read

Foundational AI models predict weekly blood sugar fluctuations

Key Takeaway:

AI models can accurately predict weekly blood sugar levels in Type 1 and Type 2 diabetes, helping patients and doctors manage diabetes more proactively.

Managing diabetes requires constant vigilance to keep blood sugar levels within a safe range. Researchers tested four advanced machine learning models to see if they could predict glucose levels a week in advance. Using data from continuous glucose monitors, the AI models successfully forecasted six key metrics, including the exact amount of time a patient's blood sugar would remain in safe or dangerous zones. This predictive capability gives patients and doctors a reliable early-warning system, allowing them to adjust insulin doses or diets before dangerous spikes or drops occur.

What this means for you

This promising research isn't available in clinics yet. It's an early study, so continue with your current diabetes care plan and consult your doctor for any changes or questions about your treatment.

Radiology Clinical Trial Endocrinology

Citation:

ArXiv, 2026. arXiv: 2601.00613 Read article →

Why the Most “Accurate” Glucose Monitors Are Failing Some Users

From: 2025-12-08

IEEE Spectrum - BiomedicalExploratory3 min read

Study reveals why highly rated glucose monitors fail users

Key Takeaway:

Dexcom's latest continuous glucose monitors may not provide consistent accuracy for all users, highlighting the need for personalized monitoring strategies in diabetes management.

An independent evaluation published in IEEE Spectrum investigated the accuracy of Dexcom's latest continuous glucose monitors. The researcher compared the digital sensor readings against traditional finger-prick blood tests in a small-scale trial. While the devices generally performed well, the study identified specific real-world factors that caused inconsistent and inaccurate readings for certain users, highlighting the need for backup testing methods.

What this means for you

Early research shows some CGMs may not be accurate for everyone. It's important not to change your care based on this study. Talk to your doctor about your specific needs and current recommendations.

Clinical Decision Endocrinology

Citation:

IEEE Spectrum - Biomedical, 2025. Read article →

Exploring Endocrinology? Learn how to interpret medical AI research →